Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.63 |
| ▸ | F2 | P00734 | 4/20 | 0.63 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.63 |
| ▸ | PLG | P00747 | 1/20 | 0.63 |
| ▸ | PLAU | P00749 | 1/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.63 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.61 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.61 |
| ▸ | F7 | P08709 | 3/20 | 0.59 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548407 | 0.94 | F10 (0.60) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL7479169 | 0.93 | F10 (0.71) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL548319 | 0.92 | F10 (0.58) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL7478562 | 0.92 | F10 (0.55) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL7477342 | 0.92 | F10 (0.64) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL27639305 | 0.91 | F10 (0.57) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL65730 | 0.90 | F10 (0.77) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL7484117 | 0.89 | F10 (0.52) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL4322200 | 0.89 | TPSAB1 (0.78) | F10F2TPSAB1PRSS1PLG | |
| SCHEMBL7487011 | 0.88 | F10 (0.75) | F10F2TPSAB1PRSS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| US-6815461-B1 | ADMINISTERING BIS-BENZIMIDAZOLE COMPOUND; TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-11-09 | — | — | US | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-0739202-B1 | USE OF BIS(AMIDINOBENZIMIDAZOLES) IN THE MANUFACTURE OF MEDICAMENT FOR INHIBITING RETROVIRAL INTEGRASE | UNIV NORTH CAROLINA (US) | 1998-12-16 | — | — | EP | claimed |
| EP-0739202-A1 | USE OF BIS(AMIDINOBENZIMIDAZOLES) IN THE MANUFACTURE OF MEDICAMENT FOR INHIBITING RETROVIRAL INTEGRASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-10-30 | — | — | EP | claimed |
| WO-1995019772-A1 | USE OF BIS(AMIDINOBENZIMIDAZOLES) IN THE MANUFACTURE OF MEDICAMENT FOR INHIBITING RETROVIRAL INTEGRASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1995-07-27 | — | — | WO | claimed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-4619942-A | Inhibition of Respiratory Syncytial virus-induced cell fusion by amidino compounds | UNIVERSITY OF NORTH CAROLINA (US) | 1986-10-28 | — | — | US | disclosed |
| US-4397863-A | PROPHYLAXIS | RESEARCH TRIANGLE INSTITUTE (US) | 1983-08-09 | — | — | US | disclosed |
| US-4397863-A | PROPHYLAXIS | RESEARCH TRIANGLE INSTITUTE (US) | 1983-08-09 | — | — | US | disclosed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | disclosed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | F10 4333/4885F2 4176/4885TPSAB1 1403/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | F10 2519/4885F2 2085/4885TPSAB1 1230/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | F10 3617/4885F2 3907/4885TPSAB1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.